Think the impossible: beta-blockers for treating asthma (Q39297594)

10 September 2017

Think the impossible: beta-blockers for treating asthma (English)

1 reference

10 September 2017

0 references

Brian J Lipworth

1

1 reference

PubMed ID

19807697

10 September 2017

Peter A Williamson

series ordinal

2

1 reference

PubMed ID

19807697

10 September 2017

language of work or name

English

0 references

publication date

12 October 2009

1 reference

10 September 2017

1 reference

10 September 2017

118

1 reference

10 September 2017

115-120

1 reference

10 September 2017

2

1 reference

Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations.

10 September 2017

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

Muscarinic receptors and control of airway smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

Is paradoxical pharmacology a strategy worth pursuing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on blood pressure in hypertensive patients known to respond to beta 1-adrenoceptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

British Guideline on the Management of Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20090398

21 January 2018

Identifiers

DOI

10.1042/CS20090398

1 reference

10 September 2017

1 reference

PubMed ID

19807697